Podcasts about Menin

Prof. Dr. Seda Demiralp ile Kemal Kılıçdaroğlu'nun CHP'ye mutlak butlan olarak atanmasından sonra seçmende oluşan duyguyu ve bunun seçime olası etkilerini konuştuk. İyi seyirler...

Enhanced Games Debut in Las Vegas as the First Openly Drug-Enabled "Biohacker Olympics" The inaugural Enhanced Games took place in Las Vegas with more than 40 elite athletes competing openly while using performance-enhancing drugs, a $25 million prize pool, and a $1 million world record bonus on the table. Host Dave Asprey, who serves on the advisory board of the Enhanced Games, breaks down why this event is less a sports story than a cultural signal: enhancement has moved from underground to prime time, and the institutions that spent decades controlling that conversation through drug testing and bans watched it happen on a stage in Las Vegas. Dave explains why WADA has always existed to protect institutions rather than athletes, why bodily sovereignty is the real issue at the center of this debate, and what it means that even with full transparency about what every athlete was taking, the records didn't fall quite the way you'd expect. The Enhanced Games are the closest thing yet to a public beta test for extreme human enhancement, and the data it generates will matter far beyond sport. Sources: https://www.nytimes.com/athletic/7302319/2026/05/23/enhanced-games-athletes-world-records-doping-steroids/ https://www.npr.org/2026/05/24/nx-s1-5831252/enhanced-games-steroids-olympics-trump https://www.bbc.com/news/articles/cedpz1zqp8po https://www.wusf.org/2026-05-24/the-enhanced-games-are-sunday-heres-what-to-know-about-the-controversial-event Kyle Busch's Death Showed How Severe Pneumonia Can Rapidly Escalate Into Fatal Sepsis NASCAR driver Kyle Busch died after severe pneumonia progressed into sepsis, a condition most people hear about but few truly understand until it is too late. Host Dave Asprey breaks down the biology of what happens when the immune system stops containing an infection and starts attacking the body systemwide, why sepsis can escalate from manageable symptoms to a life-threatening emergency faster than most people expect, and why even someone with great biomarkers and a dialed-in health stack can be blindsided by an acute inflammatory crisis. The warning signs matter: worsening breathing, confusion, rapid decline, and a sense that something is badly wrong are emergency symptoms, not signals to wait and see. Longevity is not only about optimization rituals. It includes knowing when your biology is in crisis and acting before the window closes. Sources: https://www.cnn.com/2026/05/24/health/what-is-sepsis-kyle-busch-wellness https://www.cnn.com/2026/05/26/health/video/sepsis-kyle-busch-medical-care-lead-jake-tapper https://www.michiganmedicine.org/health-lab/nascar-stars-death-shows-how-sepsis-can-kill-anyone-if-not-caught https://www.huffpost.com/entry/what-is-sepsis-kyle-busch_l_6a15a9c1e4b0ddcc84641f34 Menin Loss in the Hypothalamus May Be a Central Switch That Accelerates Aging New research in mice found that a protein called Menin in the hypothalamus may function as a central coordinator of biological aging across the whole body. When Menin declined, aging accelerated. When researchers restored it in older mice, memory improved and lifespan increased. Host Dave Asprey explains why this finding challenges the dominant wear-and-tear model of aging, what it means that the hypothalamus may be running a coordinated aging program rather than simply accumulating damage over time, and why a control-room model of aging points toward fundamentally different intervention strategies than chasing downstream symptoms like fatigue and memory loss. The research connects aging to neuroinflammation, which has direct implications for how biohackers think about hypothalamic health right now. It is still animal research, but the mechanistic case is strong and the implications for longevity science are significant. Sources: https://www.sciencedaily.com/releases/2026/05/260524012959.htm https://www.news-medical.net/news/20230323/Menin-protein-protects-against-aging-and-cognitive-decline.aspx https://www.eurekalert.org/news-releases/982100 https://www.eurekalert.org/news-releases/1116021 IL-6 Blockade With Tocilizumab Showed Early Promise for Treatment-Resistant Depression A small pilot randomized trial tested tocilizumab, an anti-inflammatory drug that blocks IL-6 signaling, in people with difficult-to-treat depression and found remission rates of 54% versus 31% with placebo. Host Dave Asprey breaks down why this result reframes depression as an immune biology problem for a meaningful subset of patients rather than a purely neurochemical one, and why the same inflammatory pathway that drives joint destruction in rheumatoid arthritis is showing up in the brains of people who don't respond to antidepressants. The practical implication is not to seek out a biologic drug off-label. It is to recognize that persistent low mood, fatigue, and low resilience may warrant a deeper biological workup than standard screening provides, starting with IL-6, CRP, and a full inflammatory panel. The brain is downstream of the immune system more than most psychiatry has been willing to admit, and this trial is the clearest evidence yet of why that matters. Sources: https://www.bristol.ac.uk/news/2026/may/pilot-trial-suggests-anti.html https://www.eurekalert.org/news-releases/1128678 https://www.medicalxpress.com/news/2026-05-trial-anti-inflammatory-drug-difficult.html https://clinicaltrials.gov/ New Science Paper Says Intrinsic Human Lifespan May Be About 50% Heritable A paper published in Science argues that the genetic contribution to human lifespan is roughly 50% heritable, far higher than previous estimates, once researchers correct for deaths caused by accidents, infections, and external causes unrelated to aging biology. Host Dave Asprey explains why this finding is liberating rather than deterministic, what it means that genetics loads the dice on lifespan more than the mainstream has been willing to admit, and why personalized longevity strategy matters far more than generic population-level advice. Your genes load the dice but you still roll them. The study pushes the field toward genetic stratification and biomarker-based personalization, and it validates the core premise that the same intervention will not produce the same outcome in every person. Get your genetics tested and build your strategy from your own baseline, not from what worked for the average person in a study. Sources: https://www.science.org/doi/10.1126/science.adz1187 https://pubmed.ncbi.nlm.nih.gov/41610249/ https://www.nature.com/articles/d41586-026-00300-w https://www.eurekalert.org/news-releases/1113892 This episode is designed for biohackers, longevity seekers, and high-performance listeners who want mechanism-level clarity on human enhancement, acute inflammatory risk, neuroendocrine aging, immune-driven depression, and the genetics of lifespan. Host Dave Asprey connects emerging clinical research, real-world performance culture, and actionable optimization frameworks into a clear picture of where biology actually drives outcomes and where most people are still managing symptoms instead of finding the mechanism. New episodes every Tuesday, Thursday, Friday, and Sunday. Keywords: Enhanced Games biohacking, performance enhancement bodily autonomy, WADA elite sport doping, Kyle Busch sepsis death, pneumonia sepsis escalation, sepsis warning signs, Menin hypothalamus aging, brain aging master switch, neuroendocrine aging longevity, tocilizumab depression IL-6, inflammation treatment-resistant depression, immune biology mental health, lifespan heritability genetics, longevity genetics personalization, genetic stratification healthspan, biohacking news 2026, longevity research 2026, healthspan optimization, inflammation testing CRP IL-6 Thank you to our sponsors! - HeartMath | Go to https://www.heartmath.com/dave to save 15% off. - The One Device | Use code DAVE for $10 off at theonedevice.com/dave - iRestore | Reverse hair loss at www.irestore.com/DAVE and get exclusive savings on the iRestore Elite, use code DAVE Resources: • Get My 2026 Clean Nicotine Roadmap | Enroll for free at https://daveasprey.com/2026-clean-nicotine-roadmap/ • Get My 2026 Biohacking Trends Report: https://daveasprey.com/2026-biohacking-trends-report/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/ • Upgrade Labs: https://upgradelabs.com Timestamps: 00:00 – Intro 00:38 – Story 1: Enhanced Games 01:49 – Story 2: Kyle Busch Death (Sepsis) 03:09 – Story 3: Menin Protein and Brain Aging 04:37 – Story 4: Inflammation and Depression 06:20 – Story 5: Lifespan Heritability 07:47 – Takeaway See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of the Oncology Brothers podcast, we dived deep into the complexities of relapsed refractory acute myeloid leukemia (AML) with expert guest Dr. Joshua Zeidner, Chief of Leukemia Research at the University of North Carolina. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Join us as we explore two challenging cases: Revumenib (menin inhibitor) demonstrated an overall response rate of ~63% in heavily pre-treated KMT2A rearrangement-positive AML patients based on the AUGMENT-101 study, with QTc prolongation and CYP3A4 drug interactions as key monitoring considerations. FLT3 inhibitors like gilteritinib and quizartinib play an important role in MRD-positive FLT3 ITD/NPM1-mutated AML post-transplant, with the MORPHO trial supporting gilteritinib as maintenance therapy.  Menin inhibitors may have a broader role in high-risk AML including NPM1-mutated disease, and re-evaluating mutational profiles at relapse is critical for optimal treatment selection.  Careful monitoring of side effect profiles, drug interactions, and MRD status is essential when navigating targeted therapy decisions in relapsed refractory AML. Throughout the episode, we discuss key practical points, including the importance of monitoring for QTc prolongation and the impact of drug interactions with CYP3A4 inhibitors. Tune in for an informative discussion that sheds light on the latest advancements in targeted therapies for AML and the evolving landscape of treatment options. Don't forget to like, subscribe, and check out our other episodes in the challenging case series, treatment algorithms, and conference highlights! #AcuteMyeloidLeukemia, #MeninInhibitor, #FLT3Inhibitor, #Hematology, #OncologyBrothers

This week, Mayor Zohran Mamdani and City Council Speaker Julie Menin appeared to set aside their differences to advance a new budget solution: scaling back a lucrative tax credit used by wealthy business owners to help close the city's budget gap. The proposal, which targets what's known as the Pass-Through Entity Tax (PTET) credit, was swiftly rejected by Gov. Kathy Hochul. NY1 investigative reporter Courtney Gross, and political reporters Bobby Cuza and Kelly Mena break down how the tax credit works, who benefits most, and why the governor pushed back. Plus: Did Mayor Mamdani take a political hit? His endorsement of Lindsey Boylan fell short in a special election for a Manhattan City Council seat, raising questions about his influence. Meanwhile, the mayor waded into international controversy after appearing to pick a fight with the King over a disputed gem. The "Off Topic" team looks at Mamdani's busy week.

A MRV é a maior empresa de habitação da América Latina. São 46 anos de história, mais de 600 mil apartamentos entregues e 1,8 milhão de brasileiros que hoje vivem em um imóvel construído por eles. Mas chegar até aqui não foi simples. Neste episódio, Rafael Menim senta com Fernando Ferreira, estrategista-chefe da XP e Ygor Altero, head de Real Estate no Research da XP, para falar abertamente sobre os ciclos do mercado imobiliário, os desafios de liderar uma das maiores construtoras do país e o momento de virada que a MRV está vivendo agora.Durante a conversa, Rafael conta como o Minha Casa Minha Vida transformou o setor e por que ele veio para ficar, explica o déficit de 6 milhões de moradias e os motivos pelos quais ele simplesmente não some, e faz um balanço honesto sobre a aventura da Résia nos Estados Unidos — o que deu errado e o que a empresa planeja para o futuro.Ele também fala sobre os desafios práticos do negócio, como a escassez de mão de obra e a pressão de custos, e detalha o novo ciclo de excelência da MRV, focado em rentabilidade, desalavancagem e geração de caixa. Tudo isso sem deixar de lado a história pessoal: de estagiário a CEO, 27 anos dentro da mesma empresa fundada pelo seu pai.-----------------------------------------------------------------------------Investir com a XP Investimentos é fácil, basta criar o seu cadastro e em minutos você já pode começar a investir: https://t2m.io/youtube-aqsAcompanhe todos os conteúdos da XP em https://t2m.io/8cxPp6xParticipe do canal do Telegram: https://t.me/xp_investimentosConfira nosso Instagram: https://www.instagram.com/expertxp/Glossário financeiro: https://conteudos.xpi.com.br/conteudos-gerais/glossario-financeiro/-----------------------------------------------------------------------------

In this podcast, experts Naval G. Daver, MD; Amir Fathi, MD; Guillermo Garcia-Manero, MD; and Aditi Shastri, MD, discuss current applications for menin inhibitors in patients with acute leukemia, combination approaches under investigation, and managing treatment-related adverse events with menin inhibitors.

24.04.2026 | Dijital Hayat Bölüm582 - TRT Radyo1 | "Dijitalleşmenin İklim Krizine Etkileri" Dr. Bilal Eren'in hazırlayıp, sunduğu Dijital Hayat programımızda bu hafta, Boğaziçi Üniversitesi İklim Değişikliği Araştırma Merkezi Yönetim Kurulu Üyesi ve İklim Bilimci Prof. Dr. Murat Türkeş ile; - Dijitalleşme ile İklim Krizi Arasındaki İlişki Nedir? - Dijitalleşmenin İklim Krizine Etkileri? - Dijitalleşme, İklim Krizi Sorununun mu, Çözümünün mü Parçası? - Karbon Ayak İzi, Sera Gazı, Elektronik Cihaz Kullanım Alışkanlıklarımız, E-Atık, Elektronik Cihaz Üretiminde Kullanılan Madenler gibi Hangi Başlıklar, İklim Krizinde Etkili? - Bireysel Dijital Kullanım Alışkanlıklarımız Nasıl Olmalı? - Birleşmiş Milletler İklim Değişikliği Konferansı (COP) Organizasyonu Konuyla İlgili Neler Yapıyor? - Türkiye'de Kasım 2026'de Düzenlenecek COP Organizasyonundan Neler Bekliyorsunuz? - Türkiye, İklim Krizi Mücadelesinde Fark Yaratabilir mi? Başlıklarını konuştuk. Dijital Hayat, her cuma saat 15:30'da TRT Radyo1 mikrofonlarında canlı yayında... Tüm geçmiş ve gelecek yayınlarımız için; Web: https://www.dijitalhayat.tv

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Menin Inhibitors in Acute Myeloid Leukemia | Faculty Presentation 2: Potential Role of Menin Inhibitors as a Component of Combination Therapy — Amir Fathi, MD CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Menin Inhibitors in Acute Myeloid Leukemia | Faculty Presentation 1: Biology Underlying the Utility of Menin Inhibitors in Acute Leukemias: Use of These Agents as Monotherapy — Eunice S Wang, MD CME information and select publications

Featuring perspectives from Dr Amir Fathi and Dr Eunice S Wang, including the following topics: Introduction: Overview — Biopharmacologic Considerations (0:00) Menin Inhibitor Monotherapy (21:51) Differentiation Syndrome (36:12) Menin Inhibitor Combination Approaches (45:15) Future Directions (49:59) PARADIGM — Randomized Phase II Trial (53:24) CME information and select publications

Why Brotherhood Matters for MenIn this episode, we break down why men were never meant to do life alone. Isolation is not strength—it is risk. We talk about how isolation impacts your faith, leadership, and family, and what the Bible says about building real brotherhood.What We CoverThe Danger of IsolationIsolation weakens men over time and creates space for poor decisions and spiritual attacks. When a man disconnects, his family feels it first.

Sivas'ta devrilen beton pompasının çarpmasıyla kalıbın içine düşen 23 yaşındaki gencecik bir işçinin yarım kalan hayalleri… Amasya'da, torun sevecek yaşta, 65 yaşında bir işçi ağabeyimizin inşaatın çatısından düşerek hayatını kaybetmesi… Eskişehir'de elektrik arızasını gidermeye çalışırken akıma kapılan işçi kardeşimiz… İzmir'de arıtma tesisinde kullandığı atık toplama kamyonu çamurla dolu çukura düşen işçi kardeşimiz… Ve Dilovası'ndaki Çolakoğlu Metalurji… Birkaç metrelik basit bir yaşam halatının çok görülmesi yüzünden metrelerce yükseklikten beton zemine çakılarak yaşamını yitiren sınıf kardeşlerimiz… 8 Kasım'da Dilovası'nda Ravive Kozmetik adlı parfüm fabrikasında, bir dizi ihmal sonucu hayatını kaybeden 3 evladımız, 4 kız kardeşimiz…Ülkede resmen her gün yeni bir isimsiz mezar kazılıyor, fabrikalardan, şantiyelerden, tersanelerden, madenlerden çıkan cansız bedenler bu isimsiz mezarları dolduruyor. Yaşanan ölümlerin hiçbiri tesadüf değil. Hiçbiri talihsizlik değil. Hiçbiri işçinin bir anlık dalgınlığının sonucu değil. Ve en önemlisi, hiçbiri “görünmez kaza” değil. Her biri göz göre göre gelen, patronların kârını her şeyin üstünde tutan bu düzenin eseri. Ve sermaye düzeni bu cinayetlerin sadece faili değil, aynı zamanda sorumluları aklamanın, cezasızlıkla cesaretlendirmenin de aracı. 3'ü çocuk 7 işçi kardeşimizin yaşamını yitirdiği Ravive Kozmetik davası en çarpıcı örneklerden birisiydi. Ravive Kozmetik'te fabrika binası kaçaktı. İşçiler kayıt dışı ve sigortasız çalıştırılıyordu. Fabrikada herhangi bir güvenlik önlemi alınmadığı gibi, denetim de yapılmıyordu. Bu şartlarda göz göre gelen iş cinayetinin tek sorumlusu yalnızca patron değil. Patrona bu denli göz yuman, adeta her türlü denetimden muaf tutan düzenin kurumları da sorumluydu. Giden geri gelmiyor ama işçi ailelerinin yüreğine bir nebze olsun su serpecek şey “adaletin yerini bulması” olurdu. Ne var ki devlet, mahkemenin kendisini emekçi halktan, sorumluları da adaletten kaçırmaya çalıştı. Mahkeme heyeti türlü ihlaller yaptı, işçi ailelerinin avukatlarının her türlü talebini reddetti. Emekçi halkın adalet talebi, sermayenin yasalarının hâkim olduğu mahkeme koridorlarında yankısız kaldı. Birkaç yetkilinin feda edildiği, patronların “taksir” kelimesinin arkasına saklanarak kendini kurtardığı, caydırıcılıktan uzak cezalarla geçiştirilen bir tablo ortaya çıktı. Soma'da, Ermenek'te, Amasra'da gördük. İliç'te, Gayrettepe'de, Dilovası'nda görüyoruz. Bu durumun değişmesi gerek ama bu, servetinden başka bir şey düşünmeyen patronların insafına da onları koruyup kollayan yasalarla sözde adaleti sağlayacak mahkemelerin vicdanına da bırakılamaz. Elbette mahkemelerde sorumluların ceza alması için mücadele edeceğiz. Elbette işyerlerinde, fabrikalarda gerekli tedbirlerin alınmasını sağlamak için mücadele edeceğiz. Ama yarım hayatların önüne gerçekten geçmek için, fabrikalarda, işyerlerinde patronların orman kanunlarının hüküm sürdüğü değil, işçi sağlığının ve iş güvenliğinin gereklerini hâkim kılacak bir düzen gerek. Patronların işçinin hayatından çalmasını engellemek için işçi denetimi gerek. Bu da ancak örgütlenerek mümkün. Tek tek fabrikalarda, işyerlerinde sendikalarımızda örgütlenerek... Ama tek bir kişi daha eksilmeyeceğiz diyorsak o zaman bu kanlı çarkın son bulması, patronların kâr hırsının değil, işçi sınıfının iktidarının hâkim olması gerek. Bunun için tek tek fabrikalarda sendikalarda örgütlenmek yetmez, bunun için çağrımız devrimci sınıf siyasetinde örgütlenme çağrısı. 28 Nisan “İş Cinayetlerinde Hayatını Kaybeden İşçileri Anma Günü”. İlk kez 1914'te 28 Nisan günü, Kanada'da bir mahkemenin iş kazalarında patronların sorumlu olduğuna dair verdiği bir karara atfen bu tarih kabul edilmiş. 28 Nisan'da onları anacağız. 28 Nisan'dan sonra 1 Mayıs var. 1 Mayıs meydanlarında, iş cinayetlerinde yitirdiğimiz işçiler için de yürüyeceğiz. Hem onların hesabını sormak hem tek bir kişi daha eksilmemek için sınıf siyasetinin sesini yükseltmek için!

NYC Council member Tiffany Cabán (District 22, Astoria, Jackson Heights, East Elmhurst, Woodside and Rikers Island) talks about the Delivery Protection Act, which would regulate "last mile" delivery subcontracting by retail giants like Amazon, and Mayor Mamdani's first 100 days in office. Photo: An Amazon Prime delivery van parked in Hillcrest, Queens. Credit: Tdorante10 via Wikimedia Commons.    

It's Casual Friday on The Majority Report   On today's program:   Julie Menin, the multimillionaire Speaker of the New York City Council, is opposing Mayor Zohran Mamdani's budget proposal by responding to a moderate tax increase on the ultra-wealthy with cuts to city programs. Unrelated, Menin owns a $22 million mansion in the Hamptons and a $7 million apartment on the Upper East Side. No conflict of interest there.   Heather 'Digby' Parton joins the program to recap the week's news. Check out Digby's work at Salon as well as her blog Hullabaloo. Topics include the American right-wing's desperation to keep Victor Orban in power in Hungary, Trump firing all the women around him, Iran and more. Trump In the Fun Half:   Harry Enten presents polling that shows Congressional democrats' ratings are in the toilet.   Joe Rogan gets very uncomfortable every time Theo Von brings up the genocide in Palestine.   Matt Gaetz tells Benny Johnson about an alleged briefing he got from a uniformed servicemember about an interspecies breeding program between aliens and people captured in warzones operated by the CIA.   Karoline Leavitt is fighting to keep her job by flattering Trump in typical North Korean style ass kissing.   Megyn Kelly is not happy with the Trump's administration's handling of the war of Iran.   A couple of pastors from Pete Hegseth's denomination perform unconvincing toxic masculinity - these guys are certainly not hiding from themselves.   all that and more   Preorder Molly Crabapple's book: Here Where We Live is Our Country.   To connect and organize with your local ICE rapid response team visit ICERRT.com The Congress switchboard number is (202) 224-3121. You can use this number to connect with either the U.S. Senate or the House of Representatives. Follow us on TikTok here: https://www.tiktok.com/@majorityreportfm Check us out on Twitch here: https://www.twitch.tv/themajorityreport Find our Rumble stream here: https://rumble.com/user/majorityreport Check out our alt YouTube channel here: https://www.youtube.com/majorityreportlive Gift a Majority Report subscription here: https://fans.fm/majority/gift Subscribe to the AMQuickie newsletter here: https://am-quickie.ghost.io/ Join the Majority Report Discord! https://majoritydiscord.com/ Get all your MR merch at our store: https://shop.majorityreportradio.com/ Get the free Majority Report App!: https://majority.fm/app Go to https://JustCoffee.coop and use coupon code majority to get 10% off your purchase Check out today's sponsors: WILD GRAIN: Get $30 off your first box + free Croissants in every box. Go to Wildgrain.com/MAJORITY to start your subscription..   SUNSET LAKE: Use coupon code "Left Is Best" (all one word) for 20% off of your entire order at SunsetLakeCBD.com  Follow the Majority Report crew on Twitter: @SamSeder @EmmaVigeland @MattLech On Instagram: @MrBryanVokey Check out Matt's show, Left Reckoning, on YouTube, and subscribe on Patreon! https://www.patreon.com/leftreckoning Check out Matt Binder's YouTube channel: https://www.youtube.com/mattbinder Subscribe to Brandon's show The Discourse on Patreon! https://www.patreon.com/ExpandTheDiscourse Check out Ava Raiza's music here! https://avaraiza.bandcamp.com

In this podcast, experts Naval Daver, MD; Courtney DiNardo, MD; and Eunice Wang, MD; discuss the rationale for treatment with menin inhibitors—and the data showing their efficacy and safety—in acute myeloid leukemia (AML).

Former New York City Councilman Bob Holden calls in to discuss Council Speaker Julie Menin's tweet about combating Islamophobia, which Sid and Holden criticize in light of recent terrorist attacks and rising antisemitism; Holden argues Menin and most City Council Democrats cater to the far-left for ambition and electoral security. They discuss internal Council dynamics, Holden's view that prior Speaker Adrienne Adams was the worst, and Sid's belief Menin is more dangerous because she presents as moderate. Both condemn Menin's actions against Councilwoman Vicki Paladino and praise Paladino's popularity and outspoken views. Learn more about your ad choices. Visit megaphone.fm/adchoices

Chalkbeat, Kamar Samuels' cabinet: Your guide to the Education Department's new leadership team https://www.chalkbeat.org/newyork/2026/03/05/kamar-samuels-nyc-education-department-cabinet-leadership-team/ NY Times, U.S. Schools Are Betting Big on A.I. Will New York City Be Next?, https://www.nytimes.com/2026/03/02/nyregion/nyc-ai-schools-mamdani.html Petition calling for Moratorium on AI https://actionnetwork.org/petitions/please-enact-a-two-year-moratorium-on-the-use-of-ai-in-nyc-public-schools?clear_id=true Why bills restricting protests around schools are unwise and unfair by Rasheedah Brown-Harris, https://nycpublicschoolparents.blogspot.com/2026/03/why-bills-restricting-protests-around.html Columbia Spectator, Demonstrators outside of City Hall protest ‘buffer zone' legislation to limit protests outside schools and religious spaces, [https://www.columbiaspectator.com/city-news/2026/03/02/demonstrators-outside-of-city-hall-protest-buffer-zone-legislation-to-limit-protests-outside-schools-and-religious-spaces At hearing, Menin gets mixed feedback on her protest barrier billhttps://www.cityandstateny.com/politics/2026/02/hearing-menin-gets-mixed-feedback-her-protest-barrier-bill/411699/ Unions, NYCLU Slam Bills That Would Grant Police More Power Over Protestshttps://www.thecity.nyc/2026/02/25/faculty-unions-menin-protest-bill/ What to Know About the ‘Abortion Clinic' Law Being Used to Charge Don Lemonhttps://www.nytimes.com/2026/01/30/us/politics/face-act-lemon-explainer.html AQE letter, Tell City Council: NO NYPD buffer zones, protect free speech, protect students!https://actionnetwork.org/letters/tell-city-council-no-nypd-buffer-zones-protect-free-speech-protect-students

Mental Wealth: Why Emotional Intelligence Is the Real Power Move for MenIn a world that constantly tells men to focus on money, success, and status, one of the most important skills for long-term success is often ignored — emotional intelligence.Many men are taught to suppress emotions rather than understand them. Over time, that lack of emotional awareness can lead to burnout, relationship struggles, isolation, and mental health challenges.In this episode of SAUNAIE, we explore why emotional intelligence is one of the most powerful tools a man can develop for leadership, personal growth, and mental well-being.You'll learn why emotional awareness isn't weakness — it's a strategic advantage that improves communication, decision-making, and long-term success.If you've ever felt disconnected, misunderstood, or emotionally overwhelmed while trying to maintain discipline and focus, this conversation will help you understand why.What You'll Learn in This Episode• What emotional intelligence actually is and why it matters• The five core components of emotional intelligence• Why many men struggle with emotional awareness• How suppressed emotions affect mental health and relationships• Practical ways to build emotional intelligence in daily life• How emotional intelligence improves leadership and communication• Why self-awareness is the foundation of personal growthKey TakeawayTrue success isn't just about external achievements like money, status, or productivity.Real success also requires mental clarity, emotional awareness, and internal stability.Developing emotional intelligence helps you build stronger relationships, make better decisions under pressure, and maintain peace of mind while pursuing your goals.This is what we call mental wealth.Join the SAUNAIE CommunityThe conversations don't stop when the episode ends.Visit the SAUNAIE website to join the growing community focused on:• Mental health• Personal growth• Discipline• Self-awareness• Building stronger menSubscribe to the email list to receive new episodes, insights, and resources designed to help you grow mentally and emotionally.Share the EpisodeIf this episode resonated with you, share it with someone who may benefit from the conversation.Mental health discussions become more powerful when more people are willing to talk about them.Connect With SAUNAIEPodcast: SAUNAIEListen on: Apple Podcasts | Spotify

Tiyatro eğitiminin ardından kariyerine sahne arkasında başlayan ve bugüne dek Saatleri Ayarlama Enstitüsü, Aşık Shakespeare, Afife ve Palamut Zamanı gibi oyunlarda usta yönetmenlere yardımcı yönetmenlik yapan Serin Öztoprak; dört yazarın ortak kaleminden çıkan Uyku Ölüm Dondurma Ülke oyunuyla hem yazar hem de yönetmen olarak seyirci karşısına çıkıyor.Öztoprak; otobiyografik öğeler taşıyan bu büyüme hikâyesini, oyundaki yurt ortamının ülke atmosferiyle kurduğu bağı, projenin kolektif üretim sürecini ve günümüz ekonomik koşullarında alternatif sahnelerde bağımsız tiyatro yapmanın zorluklarını T24'e anlattı.KÜNYE:Yazar: Bilge Çınar, Merve Asya Özgür, Serin Öztoprak, Tuğçe SemizYöneten: Serin ÖztoprakOyuncular: Bilge Çınar, Merve Asya ÖzgürYardımcı Yönetmen: Tuğçe SemizMüzik: Ozan YılmazIşık Tasarım: Cem YılmazerKostüm Tasarımı: Tamar ÇıtakGörsel İletişim ve Tasarım: Mehmet EroğluKreatif Ajans: me.co studio

New York City Council Speaker Julie Menin makes her debut on the morning show with Sid to discuss Mayor Mandani's warning that property taxes could rise 9.5% if Albany, under Governor Hochul, does not raise income and corporate taxes. Menin says only the City Council has the authority to raise property taxes and states the Council has made clear any property tax increase is not up for discussion during an affordability crisis, nor are cuts to essential services. She argues the city can find savings elsewhere, highlighting escalating public sector and retiree healthcare costs (nearly $11 billion, up from $6 billion five years ago) and describing her healthcare accountability office as a way to save an estimated $2 billion annually by leveraging city purchasing power and renegotiating hospital pricing disparities. She also cites reducing reliance on no-bid contracts as another major savings opportunity, and notes upcoming budget hearings and negotiations leading to a June 30 budget deadline. Learn more about your ad choices. Visit megaphone.fm/adchoices

Councilwoman Joann Ariola calls into the show to discuss her relationships with figures like Julie Menin and Adrienne Adams, as well as their influence in New York City's political landscape. Ariola highlights Menin's effectiveness as a city council speaker and reflects on Adams joining Kathy Hochul's ticket for re-election. Transitioning to the city's pressing issues, Ariola critiques Mayor Mamdani for inadequate responses to street homelessness, particularly during a cold snap that resulted in several deaths. Ariola argues for more proactive and compassionate measures, indicating a significant alignment among council members in holding the administration accountable. Learn more about your ad choices. Visit megaphone.fm/adchoices

New York City Council speaker Julie Menin (D-5, Upper East Side) talks about the council's priorities, working with Mayor Mamdani, and new proposals—including year-round outdoor dining.

Councilwoman Vickie Paladino calls in to discuss her disappointment and anger towards New York City Council Speaker Julie Menin. Despite initially supporting Menin's bid for the position and expecting a centrist leadership approach, Paladino feels betrayed by Menin's public criticism. Paladino explains that she had a positive conversation with Menin before the criticism and maintains that the handling of the situation was inappropriate. She emphasizes her commitment to her district and her open communication across political lines, strongly defending her actions and asserting her First Amendment rights. Paladino also highlights the need for respectful and transparent interactions within the council. Learn more about your ad choices. Visit megaphone.fm/adchoices

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GFF865. CME/EBAH/AAPA/IPCE credit will be available until January 4, 2027.Menin Masters for AML Care: Guidance on Integrating Menin Inhibitor Regimens & Boosting Efficacy in Challenging AML Subtypes In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Myeloid Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GFF865. CME/EBAH/AAPA/IPCE credit will be available until January 4, 2027.Menin Masters for AML Care: Guidance on Integrating Menin Inhibitor Regimens & Boosting Efficacy in Challenging AML Subtypes In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Myeloid Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GFF865. CME/EBAH/AAPA/IPCE credit will be available until January 4, 2027.Menin Masters for AML Care: Guidance on Integrating Menin Inhibitor Regimens & Boosting Efficacy in Challenging AML Subtypes In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Myeloid Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GFF865. CME/EBAH/AAPA/IPCE credit will be available until January 4, 2027.Menin Masters for AML Care: Guidance on Integrating Menin Inhibitor Regimens & Boosting Efficacy in Challenging AML Subtypes In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Myeloid Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GFF865. CME/EBAH/AAPA/IPCE credit will be available until January 4, 2027.Menin Masters for AML Care: Guidance on Integrating Menin Inhibitor Regimens & Boosting Efficacy in Challenging AML Subtypes In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Myeloid Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GFF865. CME/EBAH/AAPA/IPCE credit will be available until January 4, 2027.Menin Masters for AML Care: Guidance on Integrating Menin Inhibitor Regimens & Boosting Efficacy in Challenging AML Subtypes In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Myeloid Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

Julie Menin, the presumptive next Speaker of the New York City Council, joined host Ben Max and Andrew Rein, president of Citizens Budget Commission, for a conversation at New York Law School on her path to the speakership, her priorities when she takes the position in January, how she plans to work with Mayor Zohran Mamdani, and more. The event took place on December 10, 2025 and was hosted by NYLS' Center for New York City and State Law and Citizens Budget Commission. Menin declared victory in the speaker race in late November, and will have to be officially voted into the position by her Council colleagues in early January. (Ep 553)

Following right-wing Democrat Julie Menin's victory in the race for City Council Speaker, we spoke with Brandon West, a former member of the City Council's central staff, about how Menin and her supporters outmaneuvered progressives, the powers she will wield as speaker and how she might try to obstruct Zohran Mamdani when he is mayor.

Eksik Olan'ın bu bölümünde Ömer Çeşit ile Alp Kozanoğlu, Mike Davis'in kült eseri “Gecekondu Gezegeni” üzerinden şehirleşmenin karanlık yüzünü tartışıyor. 2003'te yayımlanan kitap, hızla büyüyen gecekondu yerleşkelerini ve neoliberal düzenin yarattığı yapısal eşitsizlikleri mercek altına alıyor. Mega-gecekondu kentlerinin kendi iç dinamikleri, kültürel etkileri ve ekolojik sonuçları konuşuluyor. Learn more about your ad choices. Visit megaphone.fm/adchoices

Featuring an interview with Dr Ghayas Issa, including the following topics: Mechanism of action and efficacy of menin inhibitors (0:00) Presentation and management of differentiation syndrome (13:31) Role of menin inhibitors in other cancers (18:19) Case: A woman in her mid 40s with KMT2A-rearranged acute myeloid leukemia (AML) after treatment for breast cancer (20:51) Mechanisms of resistance to menin inhibition in AML (26:53) Case: A woman in her early 70s with monocytic AML and multiple mutations including NPM1 experienced complete response with ziftomenib (32:31) Mechanism of action of menin inhibitors as differentiation agents (38:05) Similarities and differences between approved and investigational menin inhibitors under clinical development for the treatment of AML (45:55) Dual targeted therapy and other novel treatment approaches under clinical evaluation with menin inhibitors (51:25) Other investigational therapeutic strategies in AML (54:39) CME information and select publications

Dr Ghayas Issa from The University of Texas MD Anderson Cancer Center in Houston discusses data guiding the use of menin inhibitors for patients with acute myeloid leukemia and select alterations. CME information and select publications here.

Featuring a slide presentation and related discussion from Dr Ghayas Issa, including the following topics: Evolution of menin inhibitors for acute myeloid leukemia (AML) (0:00) Side effects of menin inhibition (10:54) Mechanisms of resistance to menin inhibition in AML (15:08) CME information and select publications

On September 20th, 1917, at the Battle of Menin Road, Private Roy Inwood lay in the mud east of Ypres. His brother had died at Pozières the year before. In three hours, Roy would earn the Victoria Cross. The day after, he'd be dead.Nearby, three brothers from Petersham waited with their unit. By nightfall, their mother would have lost all three sons.After weeks of catastrophic failures under General Gough, Field Marshal Haig transferred command to General Herbert Plumer. In this episode, Mat McLachlan reveals how Plumer's methodical genius transformed the offensive: three weeks of preparation, limited objectives, overwhelming firepower—one gun for every five yards of front—and revolutionary tactics that reversed traditional doctrine.From predawn assembly through torrential mist to the devastating creeping barrage, we follow the 1st and 2nd Australian Divisions executing what Charles Bean called "probably their zenith"—the most perfectly coordinated attack of the war.Why did German counter-attacks fail so catastrophically? How did Plumer's "bite and hold" change tactical doctrine? What drove Roy Inwood to advance alone through his own barrage—twice?"Nothing I have heard in this world or can in the next could possibly approach its equal." - Australian soldier describing the barrageEpisode Length: 42 minutesFeatures: Frank Hurley's battlefield diary, German assessments of defensive collapse, and the Seabrook brothers' final day.Next Episode: Polygon Wood—the high point of the offensive.Presenter: Mat McLachlanProducer: Jess StebnickiReady to walk the battlefields? Join Mat's exclusive European tours: https://battlefields.com.au/Find everything Mat is doing at https://linktr.ee/matmclachlanFor more history: https://www.LivingHistoryTV.com Hosted on Acast. See acast.com/privacy for more information.

In this week's episode we'll learn about targeting NPM1 in acute myeloid leukemia. Researchers report the first clinical evidence of a menin inhibitor inducing complete remissions in AML with a NPM1 mutation. This validates NPM1 as a new therapeutic target in AML, alongside FLT3, IDH1/2, and KMT2A. Also on the podcast: targeting CD137 to prevent graft-versus-host disease. In nonhuman primates, a single dose of a CD137 antibody-drug conjugate provided long-term protection, with one important caveat: the potential for viral reactivation.Featured Articles: Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 studyA single dose of a CD137 antibody–drug conjugate protects rhesus macaque allogeneic HCT recipients against acute GVHD

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WFS865. CME credit will be available until August 21, 2026.All Rise for Innovation in AML: Processing New Developments With Menin Inhibitors in Challenging AML Subtypes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WFS865. CME credit will be available until August 21, 2026.All Rise for Innovation in AML: Processing New Developments With Menin Inhibitors in Challenging AML Subtypes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WFS865. CME credit will be available until August 21, 2026.All Rise for Innovation in AML: Processing New Developments With Menin Inhibitors in Challenging AML Subtypes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WFS865. CME credit will be available until August 21, 2026.All Rise for Innovation in AML: Processing New Developments With Menin Inhibitors in Challenging AML Subtypes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

It's the Top 10 Men! Who are the best men there ever have been? Find out here! Do you think you might be on the list? Are you one of the greatest men ever to have lived? Give it a listen and see if you are featured! Don't be sad if you're not, though.Rathergood Chat ep77 - Top Ten People Part 1: MENIn this episode, as well as the top 10 men, we also discuss electromagnet tennis, black holes, Mr Weebl, taxidermy and Victorian facial hair.Here are some timecodes for the people we talk about, in case you want to skip forward to a specific chap:02:35: Albert Einstein21:36: Spike Milligan26:16: Alexander Von Humboldt30:30: Genghis Khan38:11: David Attenborough43:36: Charles Darwin45:39: Leonardo Da Vinci48:01: Charles Dickens50:11: Dick Van Dyke53:33: Isaac Asimov57:17: Ranking Hosted on Acast. See acast.com/privacy for more information.

O 30º Congresso da The European Hematologya Association (EHA) aconteceu do dia 12 a 15 de junho de 2025 em Milão, Itália, e o Portal Afya fez a cobertura completa do evento e trouxe os principais destaques da programação científica.Neste episódio, a hematologista Luiza Lapolla aborda os principais temas discutidos no evento como: os inibidores de Menin no LMA, Ziftomenib na quimioterapia intensiva para pacientes com LMA recém-diagnosticados e estudos com temas específicos como o LD-venEx, POLAGRGO Trial e mais. Ouça agora!

#813 - Quem cede à pressão perde a missão | Pr.Diego Menin by Igreja do Amor

In this episode, we took a deep dive intro the landscape of menin inhibitors in AML with Dr. Eytan Stein from MSKCC. Here are the key trials and studies we discussed: ELN 2022 AML Classification https://ashpublications.org/blood/article/140/12/1345/485817/Diagnosis-and-management-of-AML-in-adults-2022Predictors of outcomes in adults with AML and KMT2A rearrangements: https://www.nature.com/articles/s41408-021-00557-6DOT1L inhibitor https://ashpublications.org/blood/article/131/24/2661/37193/The-DOT1L-inhibitor-pinometostat-reduces-H3K79AUGMENT 101: https://ascopubs.org/doi/10.1200/JCO.24.00826Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study: https://ashpublications.org/blood/article/doi/10.1182/blood.2025028357/537139/Menin-inhibition-with-revumenib-for-NPM1-mutatedKOMET-001: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00386-3/abstractSAVE trial: https://ashpublications.org/blood/article/144/Supplement%201/216/530724/Phase-I-II-Study-of-the-All-Oral-Combination-ofKOMET-007: https://library.ehaweb.org/eha/2025/eha2025-congress/4159213/harry.erba.ziftomenib.combined.with.intensive.induction.chemotherapy.2872B329.in.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D2882%2Aot_id%3D31560%2Amarker%3D5843%2Afeatured%3D19595MEN1 mutations: https://www.nature.com/articles/s41586-023-05755-9 

261. bölümde QNB Dijital Köprü'nün KOBİ'lere yönelik dijital dönüşüm çözümlerini mercek altına alıyoruz. Konuklarım, QNB Dijital Köprü Pazarlama, Ürün ve Marka Yönetimi Bölüm Müdürü Yasemin Akemlek ve Stratejik İş Birlikleri, Müşteri Kazanımı ve Kanal Yönetimi Bölüm Müdürü Gözde Engüzel. (00:00) – Açılış (01:33) – Yasemin Akemlek ve Gözde Engüzel'i tanıyoruz. (03:57) - 20'den fazla dijital çözümün olduğu Dijital Köprü Platformuyla ilgili bu yayında e-Ticaret , e-İhracat ve imalar sektörlerine değineceğiz. KOBİ'lere yönelik son yenilikler neler ve en çok KOBİ'ler hangi hizmetleri istiyor? (05:25) – Üretim tarafında Dijital Köprü neler yapıyor? - Skala Üretim ve Envanter Yönetimi çözümü (09:10) – Üreticilerin bu hizmeti (Skala) kullanırken izledikleri yol nasıl oluyor? Bir üretici bu hizmeti kullanmak istese nerden başlıyorsunuz, nasıl yönlendiriyorsunuz? (11:18) – KOBİ'ler geleneksel yöntemlerle çalışıyorlar, ikna etmek için nasıl ilerliyorsunuz? (12:26) – e- İhracat tarafında platform nasıl bir fayda yaratıyor? (19:30) – Pazaryerlerine ürün yükleme nasıl oluyor? - StockMount e-Ticaret Pazaryeri çözümü (21:30) – Web sitesi alt yapı hazırlamak için nasıl bir yol izleniyor - İkas e-ticaret altyapısı çözümü (22:55) – Pazar yerlerine ek olarak kendi web sitenizden satış yapmak güvenilirlik açısından ne kadar önemli? (25:14) – Yurt dışına nasıl satış yaparım? e- İhracat büyüme rakamları nasıl? Dijital Köprü bu alanda nasıl destek oluyor? Envoyo e-İhracata İlk Adım çözümü (29:37) – Finansal raporların hazırlanması konusunda Dijital Köprü nasıl destek veriyor? Fincheckup Finansal Durum Raporu çözümü Promete finansal danışmanlık çözümü (34:58) – Başarı örnekleri ve geri bildirimler… (36:07) – Son sözler (37:30) – Kitap önerileri Can Dündar – Abim Deniz Dale Carnegie - Dost Kazanma ve İnsanları Kazanma Sanatı (38:50) - Kapanış Sosyal Medya takibi yaptın mı?   Twitter -⁠⁠⁠⁠⁠⁠⁠ https://twitter.com/dunyatrendleri⁠⁠⁠⁠⁠⁠⁠ Instagram -⁠⁠⁠⁠⁠⁠⁠ https://www.instagram.com/dunya.trendleri/⁠⁠⁠⁠⁠⁠⁠ Linkedin -⁠⁠⁠⁠⁠⁠⁠ https://www.linkedin.com/company/dunyatrendleri/⁠⁠⁠⁠⁠⁠⁠ Youtube -⁠⁠⁠⁠⁠⁠⁠ https://www.youtube.com/c/aykutbalcitv⁠⁠⁠⁠⁠⁠⁠ Goodreads - ⁠⁠⁠⁠⁠⁠⁠https://www.goodreads.com/user/show/28342227-aykut-balc⁠⁠⁠⁠⁠⁠⁠   aykut@dunyatrendleri.com Bize bağış yapıp destek olmak için Patreon hesabımız – ⁠⁠⁠⁠⁠⁠⁠https://www.patreon.com/dunyatrendleri⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

In today's episode, we spoke with Naval Daver, MD, about the evolving role of menin inhibition in acute myeloid leukemia (AML) and emerging data with revumenib (Revuforj) presented across ongoing clinical trials. Dr Daver is a professor in the Department of Leukemia and director of the Leukemia Research Alliance Program at The University of Texas MD Anderson Cancer Center in Houston, Texas.

Dr. John Sweetenham and Dr. Erika Hamilton discuss top abstracts that will be presented at the 2025 ASCO Annual Meeting, including research on tech innovations that could shape the future of oncology. Transcript Dr. John Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham, and I'm delighted to be joined today by Dr. Erika Hamilton, a medical oncologist and director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute in Nashville, Tennessee. Dr. Hamilton is also the chair of the 2025 ASCO Annual Meeting Scientific Program, and she's here to tell us about some of the key abstracts, hot topics, and novel approaches in cancer care that will be featured at this year's Annual Meeting. Our full disclosures are available in the transcript of this episode. Dr. Hamilton, it's great to have you on the podcast today, and thanks so much for being here. Dr. Erika Hamilton: Thanks, Dr. Sweetenham. I'm glad to be here. Dr. John Sweetenham: Dr. Hamilton, the Presidential Theme of the Annual Meeting this year is ‘Driving Knowledge to Action: Building a Better Future,' and that's reflected in many of the sessions that will focus on action-oriented guidance to improve care for our patients. And as always, there'll be great presentations on practice-changing abstracts that will change treatment paradigms and transform care. Can you tell us about some of the hot topics this year and what you're particularly excited about? Dr. Erika Hamilton: You're right. Dr. Robin Zon's theme is ‘Driving Knowledge to Action: Building a Better Future,' and you're going to see that theme really interlaced throughout the ASCO program this year. We had a record number of submissions. Over 5,000 abstracts will be published, and there'll be about 3,000 presentations, either in oral format or poster presentations. We have 200 dynamic sessions. Many of the discussants will be highlighting key takeaways and how we can translate action-oriented guidance to better treat our patients to build a better future. Our state-of-the-art science will include a Plenary Session. This will feature presentations as well as discussion of each of the presentations for clinical late-breaking abstracts. We have Clinical Science Symposia that I'm particularly excited about this year. These will feature key abstracts as well as discussions and a foundational talk around the subject. We're covering novel antibody-drug conjugate targets, turning “cold” tumors “hot” to include CAR T, as well as the future of cancer detection. There'll be rapid oral abstracts, case-based panels, and this will also feature interactive audience polling and case discussions. I also want to highlight the community connection opportunities. There will be 13 Communities of Practice that will be meeting on-site during ASCO, and there's also really a plethora of networking opportunities for trainees and early-career professionals, a Women's Networking Center, a patient advocate space, and I'm happy to report there will also be live music out on the terrace this year at ASCO. Dr. John Sweetenham: Well, that's going to be a really great addition. I have to say, I think this is always a special time of year because excitement starts to mount as the meeting gets closer and closer. And once the abstracts are out there, I certainly personally feel that the excitement builds. Talking of abstracts, let's dive into some of the key abstracts for this year's meeting. I'd like to start out by asking you about Abstract 505. This reports on 15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer in the SOFT and TEXT trials. It assesses the benefits of adjuvant exemestane and ovarian function suppression or tamoxifen and ovarian function suppression. So, could you talk us through this and tell us what you think the key takeaways from this abstract are? Dr. Erika Hamilton: Absolutely. This is essentially the SOFT and TEXT trials. They are trials that we've been following for quite some time, evidenced by the 15-year outcome. And I think it really answers two very important questions for us regarding adjuvant endocrine therapy for patients that are facing hormone receptor-positive disease. The benefit of ovarian function suppression for one, and then second, the benefit of exemestane over tamoxifen, which is our SERM [selective estrogen receptor modulator]. So, in terms of the SOFT trial, when we talk about distance recurrence-free interval, which I really think is probably the most meaningful because secondary cancers, et cetera, are not really what we're getting at here. But in terms of distant recurrence-free interval, certainly with tamoxifen, using tamoxifen plus ovarian function suppression adds a little bit. But where we really get additional benefits are by moving to exemestane, an aromatase inhibitor with the ovarian function suppression. So, for example, in SOFT, for distant recurrence-free interval for patients that have received prior chemotherapy, the distance recurrence-free interval was 73.5% with tamoxifen, bumped up just a tiny bit to 73.8% with ovarian function suppression. But when we used both ovarian function suppression and switched to that aromatase inhibitor, we're now talking about 77.6%. It may seem like these are small numbers, but when we talk about an absolute benefit of 4%, these are the type of decisions that we decide whether to offer chemotherapy based on. So, really just optimizing endocrine therapy really can provide additional benefits for these patients. Just briefly, when we turn to TEXT, similarly, when we look at distance recurrence-free interval for our patients that are at highest risk and receive chemotherapy, tamoxifen and ovarian function suppression, 79%; 81% with exemestane and ovarian function suppression. And when we talk about our patients that did not receive chemotherapy, it increased from 91.6% up to 94.6%—very similar that 3% to 4% number. So, I think that this is just very important information when counseling our patients about the decisions that they're going to make for themselves in the adjuvant setting and how much we want to optimize endocrine therapy. Dr. John Sweetenham: Thanks so much for your insight into that. Dr. Erika Hamilton: Yeah, absolutely. So, let's turn to hematologic malignancies. Abstract 6506 reports exciting results on the new agent ziftomenib in relapsed/refractory NPM1-mutant acute myeloid leukemia. This is a phase 1b clinical activity study and safety results. This was the pivotal KOMET-001 study. And my question is, will this new agent fulfill an unmet need in this NPM1 space? Dr. John Sweetenham: Yeah, great question. And I think the answer is almost certainly ‘yes'. So, just as some brief background, NPM1 mutation is known to be a driver of leukemogenesis in around 30% of patients with AML, and it's a poor prognostic factor. And typically, about 50% of these patients will relapse within a year of their first-line therapy, and only around 10% of them will get a subsequent complete remission with salvage therapy. Menin inhibitors, which disrupt the interaction between menin and KMT2A, are known to be active in NPM1-mutated as well as in KMT2A-rearranged AML. And ziftomenib is a selective oral menin inhibitor, which in this study was evaluated at a dose of 600 mg once a day, as you mentioned, a phase 1b/2 study, which is multicenter and presented by Dr. Eunice Wang from Roswell Park. It's a relatively large study of 112 patients who were treated with this standard dose with relatively short median follow-up at this time. The median age was 69 years, and median prior therapies were two, but with a range of one to seven. And I think very importantly, 60% of these patients had previously been treated with venetoclax, and 23% of them had had a prior transplant. Looking at the results overall for this study, the overall response rate was 35%, which is actually quite impressive. Specifically for those patients in the phase 2 part of the study, around 23% achieved a CR [complete remission] or CRh [complete remission with partial hematologic recovery]. What's very interesting in my mind is that the response rates were comparable in venetoclax-naive and venetoclax-exposed patients. And the drug was very well tolerated, with only 3% of patients having to discontinue because of treatment-related adverse events. And I think the authors appropriately conclude that, first of all, the phase 2 primary endpoint in the study was met, and that ziftomenib achieved deep and durable responses in relapsed and refractory NPM1-mutated AML, regardless of prior venetoclax, with good tolerance of the drug. And so, I think putting all of this together, undoubtedly, these data do support the potential use of this agent as monotherapy and as a new option for those patients who have relapsed or refractory NPM1-mutated acute myeloid leukemia. So, let's move on a little bit more now and change the subject and change gears completely and talk about circulating tumor DNA [ctDNA]. This has been a hot topic over a number of years now, and at this year's meeting, there are quite a few impactful studies on the use of ctDNA. We have time to focus on just one of these, and I wanted to get your thoughts on Abstract 4503. This is from the NIAGARA trial, which looks at ctDNA in patients with muscle-invasive bladder cancer who receive perioperative durvalumab. Could you tell us a little bit about this study? Dr. Erika Hamilton: So, this was the phase 3 NIAGARA trial, and this is literally looking for patients with muscle-invasive bladder cancer that are cisplatin-eligible, and the addition of durvalumab to neoadjuvant chemotherapy. So here, this is a planned exploratory analysis of ctDNA and the association with clinical outcomes from NIAGARA. So, this is really the type of study that helps us determine which of our patients are more likely to have a good outcome and which of our patients are more likely not to. There were 1,000 randomized patients in this study, and 462 comprised the biomarker-evaluable population. There were about half in the control arm and half in the durvalumab arm. And overall, the ctDNA-positive rate at baseline was about 57%, or a little over half, and that had decreased to about 22% after neoadjuvant treatment. ctDNA clearance rates from baseline to pre-radical cystectomy was about 41% among those with durvalumab and 31% among those in control. And the non-pCR rate was 97% among patients with pre-cystectomy ctDNA-positive status. So, this really gives us some information about predicting who is going to have better outcomes here. We did see a disease-free survival benefit with perioperative durvalumab, and this was observed in post-cystectomy ctDNA-positive as well as the ctDNA-negative groups. Shifting gears now to GI cancer, Abstract 3506 is a long-term safety and efficacy study of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer. And this is the CodeBreaK-101 study. What are your thoughts on this study? Dr. John Sweetenham: Yeah, thanks. A very interesting study, and this abstract builds upon the phase 3 CodeBreaK-300 trial, which I think has just been published in the Journal of Clinical Oncology. This showed that the combination of sotorasib and panitumumab improved clinical outcomes in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer. The current abstract, as you mentioned, reports the CodeBreaK-101 trial. And this was a phase 1b trial where FOLFIRI therapy was added to sotorasib and panitumumab in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer. The abstract reports the overall and progression-free survival results, as well as some updated safety and response data. So, in this study, patients with this particular mutation who had received at least one prior systemic treatment but were KRAS G12C inhibitor-naive were enrolled into an expansion cohort of the CodeBreaK-101 protocol. And these patients received what apparently now recommended as the standard phase 2 dose of sotorasib of 960 mg daily, plus panitumumab and a standard dose of FOLFIRI. And the primary endpoint of the study was safety, and secondary endpoints included confirmed response, overall response, and progression-free survival, as assessed by the investigator. And by November of last year, 40 patients had been enrolled into this study. Common treatment-related adverse events were cutaneous; some patients developed neutropenia, and stomatitis was fairly widespread. Discontinuation of sotorasib because of adverse events was only seen in 1% of patients, although patients did have to discontinue because of toxicity from some of the other agents in the combination. Looking at the results of this study, the updated objective response rate was 57.5%, and the disease control rate was estimated at 92%, going on 93%, with a median time to response of 1.6 months and a median response duration of 6 months. After a median follow-up of 29.2 months, the median progression-free survival was 8.2 months, and the overall survival 17.9 months. So, the authors have concluded that this combination, including sotorasib, panitumumab, and FOLFIRI, does appear to show quite promising long-term efficacy in pretreated patients with this specific mutation. The ongoing phase 3 study they mentioned, CodeBreaK-301, is aiming to evaluate this combination against the standard of care in the first-line setting for patients with KRAS G12C-mutated colorectal cancer. So, promising results, and we'd be very interested to see how this particular combination performs in the frontline. Dr. Erika Hamilton: Fantastic. Thanks so much for sharing that. Let's shift gears again and really talk about digital technology. I feel that we're all going to have to get much better with this, and really, there are a lot of promises for our patients coming here. There are a lot of abstracts at ASCO that are focusing on innovations in digital technology, including a really interesting psychosocial digital application for caregivers of patients that are undergoing hematopoietic stem cell transplantation. Can you tell us a little bit about this? It's Abstract 11000. Dr. John Sweetenham: Yeah, absolutely. This abstract certainly caught my eye, and I think it's intriguing for a number of reasons, partly because it's app-based, and partly also because it specifically addresses caregiver burden and caregiver needs in the oncology setting, which I think is especially important. And although the context, the clinical context of this study, is hematopoietic stem cell transplantation, I think it has potential applications way beyond that. We all know that caregivers of patients undergoing stem cell transplantation have significant quality-of-life struggles. They are well-documented to have significant psychological and emotional strain before, during, and after stem cell transplantation. And this abstract describes an application called BMT-CARE, which is aimed at improving caregivers' quality of life, caregiver burden, mood symptoms, and coping skills, and so on. So, this was a single-center, randomized trial from MGH [Massachusetts General Hospital] of this app for stem cell transplant caregivers, compared with usual care in those individuals. And the eligible patients, or eligible individuals, were adults caring for patients with heme malignancy undergoing either an autologous or an allogeneic stem cell transplant. Patients were randomly assigned either to use the app or for usual care. And the app itself—and I think it'll be interesting to actually see this at the meeting and visualize it and see how user-friendly and so on it is—but it comprises five modules, which integrate psychoeducation, behavior change, stress management, and they're delivered through a kind of interactive platform of educational games and videos. And then participants were self-reporting at baseline and then 60 days after transplant. So, around 125 patients were enrolled in this study, of around 174 who were initially approached. So, just over 70% uptake from caregivers, which is, I think, relatively high, and evenly distributed between the two randomized arms. And the majority of the participants were spouses. And at 60 days post-stem cell transplant, the intervention participants reported a better quality of life compared with those who received usual care. If you break this down a little bit more, these participants reported lower caregiving burden, lower incidence of depression, fewer PTSD symptoms, and overall better coping skills. So, the authors conclude that this particular app, a digital health intervention, led to pretty substantial improvements in quality of life for these caregivers. So, intriguing. As I said, it'll be particularly interesting to see how this thing looks during the meeting. But if these kind of results can be reproduced, I think this sort of application has potential uses way beyond the stem cell transplant setting. Dr. Erika Hamilton: Yeah, I find that just so fascinating and very needed. I think that the caregiving role is often underestimated in how important that is for the patient and the whole family, and really giving our caregivers more tools in their toolbox certainly is quite helpful. Dr. John Sweetenham: Absolutely. Well, the meeting is getting closer, and as I mentioned earlier, I think anticipation is mounting. And I wanted to say thanks so much to you for chatting with me today about some of the interesting advances in oncology that we're going to see at this year's meeting. There is a great deal more to come. Our listeners can access links to the studies we've discussed today in the transcript of this episode. I'm also looking forward, Dr. Hamilton, to having you back on the podcast after the Annual Meeting to dive into some of the late-breaking abstracts and some of the other key science that's captured the headlines this year. So, thanks once again for joining me today. Dr. Erika Hamilton: Thanks so much for having me. Pleasure. Dr. John Sweetenham: And thank you to our listeners for joining us today. Be sure to catch my “Top Takeaways from ASCO25.” These are short episodes that will drop each day of the meeting at 5:30 p.m. Eastern Time. So, subscribe to the ASCO Daily News Podcast wherever you prefer to listen, and join me for concise analyses of the meeting's key abstracts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   More on today's speakers: Dr. John Sweetenham   Dr. Erika Hamilton @erikahamilton9   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:     Dr. John Sweetenham:     No relationships to disclose  Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson   Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics

Continuing our journeys along the roads which crisscross the landscape of the Western Front, we travel to Flanders in Belgium, and take the old Roman road between the city of Ypres and the town of Menin which follows the story of four years of conflict here in the First World War and discuss once more the 'culture' of The Old Front Line.Got a question about this episode or any others? Drop your question into the Old Front Line Discord Server or email the podcast.Send us a textSupport the show

Director Andrew Kightlinger IG@Andrew.vhs and DP Idan Menin IG:@idanmenin talk about their film, from Sylvester Stallone's Balboa Productions, "Lost On a Mountain in Maine" https://www.lostonamountaininmainemovie.com/Matt and Oren go deep about the tough trade-offs they made between budget, VFX, and the need to look realistic. And the guys delve into a wider discussion about the dance between great cinematography and awesome storytelling. Can you shoot on an iPhone and use it alongside an Alexa 35? Would you do it In a commercial, but not in a film and why? And how do you build a relationship between you, as director and your DP that elevates everyone's reel?As always, Oren and Matt get behind the real story to working on a film produced by Sylvester Stallone. Don't miss these juicy details!!---Get a great deal on Magic Mind! https://magicmind.com/shootitjanMatt's Endorsement: Go to a nice movie theater! Oren's Endorsement: Every Frame A Picture's video on YouTube, "Where Do You Put the Camera?" https://youtu.be/wa1O3nqW5hQ?si=ttIU6t8vY0JGhIOeAndrew's Endorsement: "Paradise" on Hulu https://press.hulu.com/shows/paradise/Idan's Endorsement: The liquid emulsion process for creating photographs on a silver-based, liquid photographic emulsion adhered to unconventional surfaces like wood blocks or concrete. Get bonus content on Patreon Hosted on Acast. See acast.com/privacy for more information.